Key facts
- Oxford Drug Design’s last known valuation is $12.7M (Dec 2025).
- It has raised $16.5M; the latest was Later Stage VC ($900K) in Dec 2025.
- Notable investors include Innovate UK, European Commission, SyndicateRoom, University of Oxford, Cambridge Angels — 22 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 22 names
- ·Watchlist + deal alerts for Oxford Drug Design
- ·The full record, as it builds
Funding rounds
No funding rounds for Oxford Drug Design are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Oxford Drug Design
Developer of an artificial intelligence-driven drug discovery platform designed to support the identification and development of new therapeutic candidates. The company's platform integrates computational modeling, machine learning, generative molecular design, structure-based and ligand-based methods, and proprietary chemical representations, enabling pharmaceutical and biotechnology organizations to systematically generate, evaluate, and optimize drug candidates with improved feasibility, target relevance, and progression efficiency.
- Sector
- Healthcare
- HQ
- Oxford, United Kingdom
- Founded
- 2001
- Employees
- 10
- Website
- oxforddrugdesign.com/
- Ownership
- Privately Held (backing)
Oxford Drug Design doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Oxford Drug Design shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Oxford Drug Design in its N-PORT filings yet. We sweep new filings monthly.